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While the number of studies of the non-medical use of prescription drugs to augment
cognitive functions is growing steadily, psychological factors that can potentially help
explain variance in such pharmaceutical cognitive enhancement (CE) behavior are often
neglected in research. This study investigates the association between the Big Five
personality traits and a retrospective (prior CE-drug use) as well as a prospective
(willingness to use CE drugs) measure of taking prescription drugs with the purpose of
augmenting one’s cognitive functions (e.g., concentration, memory, or vigilance) without
medical necessity. We use data from a large representative survey of German employees
(N = 6454, response rate = 29.8%). The Five Factor Model (FFM) of Personality was
measured with a short version of the Big Five Personality Traits Inventory (BFI-S), which
includes: openness to experience, conscientiousness, extraversion, agreeableness, and
neuroticism. Together with this, demographic variables such as gender, age, education,
and income were used as potential confounders in multiple logistic regression models.
Our results show a 2.96% lifetime prevalence of CE-drug use and a 10.45% willingness
to (re)use such drugs in the future. We found that less conscientious and more neurotic
respondents have a higher probability of prior CE-drug use and a greater willingness to
use CE drugs in the future. No significant effects were found for openness, extraversion,
or agreeableness. Prior CE-drug use was strongly associated with a greater willingness
to take such drugs in the future. This study shows that specific personality traits are not
only associated with prior enhancement behavior, but also affect the willingness to (re)use
such drugs. It helps increase understanding of the risk factors of CE-drug use, which is a
health-related behavior that can entail severe side-effects for consumers. The knowledge
gathered can thus help improve interventions aimed at minimizing health problems.
Keywords: pharmaceutical cognitive enhancement, non-medical use of prescription drugs, substance abuse, drug
misuse, five-factor model, personality traits
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INTRODUCTION
Personality traits, which can be described as differences between
individuals regarding their behavior, thoughts, and feelings, can
be seen as relatively stable in different situations and over time
(Caspi, 1998; McCrae and Costa, 2008; Specht et al., 2014).
These traits are important predictors of numerous personal,
interpersonal, and social/institutional outcomes (Booth-Kewley
andVickers, 1994; Soldz andVaillant, 1999). Among these are, for
instance, happiness, physical and psychological health, longevity,
criminal activity, and occupational choices (Booth-Kewley and
Vickers, 1994; Ozer and Benet-Martinez, 2006; John et al.,
2008). Personality traits (e.g., sensation seeking, neuroticism,
impulsivity, anxiety) also seem to be variously associated with the
use of different classes of substances and consumption intentions
and therefore with risky health behavior that can have deleterious
health consequences later in life (e.g., Herman-Stahl et al., 2006;
Terracciano et al., 2008; Weyandt et al., 2009; Atherton et al.,
2014; N’Goran et al., 2014; Maier et al., 2015).
In this study, we focus on the relationship between personality
traits and the non-medical use of prescription drugs (e.g.,
methylphenidate, modafinil, donepezil) with the subjective
aim of augmenting one’s cognition (Glannon, 2008; Repantis
et al., 2010; Smith and Farah, 2011). These drugs are usually
prescribed to treat medical conditions, e.g., attention deficit
disorder, narcolepsy, dementia, or Alzheimer’s disease. This
kind of cognitive enhancement (CE) can be defined as the
intended or expected improvement of cognitive functions in
healthy individuals in order to augment concentration, vigilance,
memory, wakefulness, etc. (e.g., Bostrom and Sandberg, 2009;
Repantis et al., 2010; Sattler and Wiegel, 2013)1. Given that
clinical studies show that the effects of CE with current drugs
are limited and sometimes even detrimental (Glannon, 2008;
Repantis et al., 2010; Smith and Farah, 2011; Ragan et al.,
2013), expectations regarding effectiveness seem often to be
exaggerated (Repantis et al., 2010) while at the same time there
are also potential risks in terms of side-effects and long-term
health consequences (Sussman et al., 2006; Maher, 2008;Winder-
Rhodes et al., 2010; Ragan et al., 2013). Beside these risks,
the ethical debate about CE-drug use discusses several other
potential negative consequences such as whether it undermines
authenticity, amounts to cheating/is unfair, increases social
inequality, results in direct or indirect coercion to also use such
drugs, can burden the health care system, and can result in
the involvement of the criminal justice system (Glannon, 2008;
Greely et al., 2008; Bostrom and Sandberg, 2009; McLarnon et al.,
2012; Dubljevic´ et al., 2014; Sattler, in press).
Despite the possible detrimental effects and (long term)
side effects of CE (Sussman et al., 2006; Glannon, 2008;
1In our study, we focus on prescription drugs that seem to dominate the current
debate (e.g., Farah et al., 2004; Glannon, 2008; Greely et al., 2008; Racine and
Forlini, 2010; Smith and Farah, 2011; Ragan et al., 2013; Schelle et al., 2014;
Sattler, in press). Among these are drugs such as prescription stimulants (e.g.,
methylphenidate), antidementives (e.g., donepezil), and antidepressants (e.g.,
fluoxetine). The term “cognitive enhancement” generally encompasses the use of
various potential enhancement means such as illegal drugs (e.g., cocaine), over-
the-counter drugs (e.g., guarana), drugs naturally synthecized in the body (e.g.,
insulin), but also non-substance-based means such as mental training, sleep, brain
stimulation (e.g.,Bostrom and Sandberg, 2009; Dresler et al., 2013).
Maher, 2008; Repantis et al., 2010; Winder-Rhodes et al., 2010;
Smith and Farah, 2011; Ragan et al., 2013), healthy individuals
take such medication for enhancement purposes. In addition
to several studies questioning students about their CE use
(Middendorff et al., 2012; Maier et al., 2013; Sattler and Wiegel,
2013; Wolff and Brand, 2013; Singh et al., 2014), only a few
have surveyed the general population including the working
population or parts of it. An informal survey among 1400 readers
of the magazine Nature reported that 20% have already used
such drugs for non-medical reasons to improve concentration,
focus, or memory; these include methylphenidate (like Ritalin),
modafinil (like Provigil), beta blockers (like propranolol), and/or
others (Maher, 2008). The reported 12-month prevalence in
a representative German study was 1.5% for drugs used to
increase cognition and/or mood including prescription drugs
(e.g., drugs counteracting depression such as fluoxetin and/or
beta blockers) and illicit drugs (i.e., chemically synthesized
stimulants such as amphetamines; Hoebel et al., 2011). A German
health insurance company’s survey of employees covered under
its plans found that 4.7% used such drugs (i.e., stimulants
such as methylphenidate, antidementives such as donepezil,
and/or antidepressants such as fluoxetin) during their lifetime
to enhance cognition and/or mood (DAK Gesundheitsreport,
2009) in a follow-up study prevalence increased to 6.7%, whereby
3.3% used drugs for CE (Marschall et al., 2015). Among German
university teachers fewer than 1% reported prior non-medical use
of prescription drugs to enhance cognitive performance (without
specifying drugs or drug classes); however, more than 10% were
willing to use such drugs in the future (Wiegel et al., 2015).
This elevated willingness could turn into behavior under certain
conditions, e.g., improved benefit-risk ratio or easier access
(Singh et al., 2014; Wiegel et al., 2015), which would contribute
to the predicted trend of increased CE-drug use.
Existing prevalence estimates are very heterogeneous,
however. This is mainly due to inconsistent methods and
measures across studies (Smith and Farah, 2011; Ragan et al.,
2013; Ford and Ong, 2014; Maier et al., 2015; Sattler, in press).
Most studies are not based on probability samples, but instead
use small-scale samples, special populations, or combine
prescription and illicit drugs or mood and CE into a single
category. Thus, to get better estimates of the prevalence of CE-
drug use, large-scale population-based probability samples have
been strongly recommended (Hoebel et al., 2011; Mache et al.,
2012; Sattler et al., 2013a; Fitz et al., 2014; Sattler, in press). Given
the potential negative consequences of CE-drug use mentioned
above, more empirical data about prevalence are needed on a
regular basis for decision-making about the regulation of these
drugs (Ragan et al., 2013; Maier and Schaub, 2015) to be better
informed and also because of the assumption that the spread of
CE drugs on the world market and on the Internet can scarcely be
stopped (Sahakian and Morein-Zamir, 2007). More importantly,
however, it is necessary to develop a better understanding of the
antecedents to CE as a risky health-related behavior in order
to inform prevention policies and to develop interventions for
reducing its potential negative consequences (Booth-Kewley and
Vickers, 1994; Terracciano et al., 2008).
While we can observe an increase in the number of studies
that explore social, personal, and the characteristics of the
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substances as correlates of CE-drug use and willingness to use
CE (Sattler and Wiegel, 2013; Wolff and Brand, 2013; Sattler
et al., 2013a,b; Dubljevic´ et al., 2014; Ford and Ong, 2014; Singh
et al., 2014; Wolff et al., 2014; Maier et al., 2015; Wiegel et al.,
2015), we still know very little about the role of psychological
variables in relation to CE, in particular how personality
characteristics affect CE-drug use. Accordingly, researchers have
called for more studies on the effects of psychological variables
(Quednow, 2010; Schelle et al., 2014; Wolff et al., 2014; Ponnet
et al., 2015). Previous studies, for example, found that high
achievement motivation (Franke et al., 2012), the inclination
to procrastinate (Sattler et al., 2014; Ponnet et al., 2015), risk
attitudes (Sattler and Wiegel, 2013; Sattler et al., 2014), stress
(Wolff and Brand, 2013; Wiegel et al., 2015), high pressure to
perform (Franke et al., 2013), cognitive test anxiety (Sattler and
Wiegel, 2013; Sattler et al., 2014), trait impulsivity (Maier et al.,
2015), Machiavellianism (Maier et al., 2015), novelty seeking
(Maier et al., 2015), lower cognitive empathy (Maier et al., 2015),
and burnout (Wolff et al., 2014) were positively associated with
CE-drug use or willingness to use. Our study aims at increasing
our knowledge about the antecedents of CE-drug use by further
investigating the relationship between personality characteristics
and CE. Since it is advisable to employ multidimensional
systems of personality with a well-validated factor structure
(Sher et al., 2000), we use the Five-Factor Model (FFM) of
personality, which is a widely used and dominant paradigm
in personality psychology (Costa and McCrae, 1995; Ozer
and Benet-Martinez, 2006; Terracciano et al., 2008). It covers
the five major traits: openness to experience, conscientiousness,
extraversion, agreeableness, and neuroticism (Costa andMcCrae,
1995; Terracciano et al., 2008).
To our knowledge, this is the first study using a representative
large-scale sample of German employees to investigate how
personality traits are associated with CE. The only existing study
that has examined the Big Five personality traits and a broad
retrospective measure of CE (by combining certain prescription,
non-prescription, and illegal drugs) with bivariate analyses is
based on a student sample; the results are described below
(Middendorff et al., 2012). Given this lack of research, our study
can be informed by studies on the Big Five personality traits and
other forms of substance use andmisuse such as tobacco, alcohol,
prescription stimulants, marihuana, etc.
Openness to experience can be described as a person’s
appreciation of new experiences and stimulation due to being
imaginative, creative, unconventional, and emotionally as well
as aesthetically sensitive (Caspi et al., 2005; John et al., 2008;
Terracciano et al., 2008). It has been assumed that this willingness
to engage in new experiences is a risk factor for the non-medical
use of prescription drugs (Benotsch et al., 2013) and/or for
detrimental substance use (Turiano et al., 2012). Specifically for
CE, a greater openness to experiences has been presumed to
promote CE-drug use due to higher eagerness to experiment
(Middendorff et al., 2012). Several studies corroborate this
assumption by showing that, for example, higher openness was
positively associated withmarijuana use (Terracciano et al., 2008)
or illegal drug use in general (Turiano et al., 2012), opioid
dependency (Kornør and Nordvik, 2007), cigarette smoking
(Turiano et al., 2012), problem drinking (Turiano et al., 2012),
a broader measure of substance-related risk-taking (defined as
drinking, driving after drinking, smoking tobacco; Booth-Kewley
and Vickers, 1994), substance-use disorder (Trull and Sher,
1994), and the non-medical use of prescription drugs (Benotsch
et al., 2013). However, the only existing study of a set of different
CE drugs found no effect (Middendorff et al., 2012).
Conscientiousness refers to an ability to control behavioral
and cognitive impulses “that facilitates task- and goal-directed
behavior, such as thinking before acting, delaying gratification,
following norms and rules, and planning, organizing, and
prioritizing tasks” (John et al., 2008, p. 138; cf. Caspi et al.,
2005; Terracciano et al., 2008). It is seen as a protective factor
against the non-medical use of prescription drugs (Benotsch
et al., 2013) and the latter’s specific form of CE-drug use
(Middendorff et al., 2012), but also more generally against the
detrimental use of other substances (Turiano et al., 2012). High
levels of conscientiousness are assumed to play an important self-
regulatory role and are associated with discipline and persistence
and thus with disregarding the immediate gratification of
health-damaging behaviors in order to obtain future, long-term
outcomes (such as long-term health) “instead of” positive future,
long-term health (Middendorff et al., 2012; Turiano et al., 2012;
Benotsch et al., 2013). One argument is that since a reduced
ability to engage in systematic and organized behavior has
detrimental effects on learning, CE-drug use might be a means
to compensate for these effects (Middendorff et al., 2012). Prior
research has shown that procrastination, which can be seen as
an example of this reduced ability, predicts a willingness to use
CE drugs (Sattler et al., 2014). The only study on CE-drug use
and conscientiousness thus far has also described a negative
association between the two, namely that more conscientious
students less were less likely to report using several drugs for
purposes of CE (Middendorff et al., 2012). Furthermore, for a
majority of respondents, CE-drug use violates social norms (e.g.,
fairness; Sattler et al., 2013b; Dubljevic´ et al., 2014; Schelle et al.,
2014;Wiegel et al., 2015; Sattler, in press) and since conscientious
individuals tend to follow norms and rules, they might be less
likely to use such drugs. Research on other types of substance use
also found that increased conscientiousness is associated with a
lower incidence of cigarette smoking (Terracciano et al., 2008;
Turiano et al., 2012), of non-medical use of prescription drugs
(Turiano et al., 2012; Benotsch et al., 2013), of use of illegal
drugs such as marijuana, cocaine, and hallucinogens/lysergic acid
diethylamide (LSD) (Terracciano et al., 2008; Turiano et al.,
2012), of alcohol consumption (Malouff et al., 2007; Turiano
et al., 2012), of substance use disorders (Trull and Sher, 1994),
and specifically of opioid dependency (Kornør and Nordvik,
2007) as well as lower more general measures of the use of
substances including cigarettes, alcohol, and recreational drugs
(Atherton et al., 2014; cf., Lackner et al., 2013).
Extraversion reflects an energetic approach toward the world
and can be understood as a person’s tendency to be outgoing,
expressive, active, energetic, assertive, cheerful, sociable, and
in search of stimulation (Caspi et al., 2005; John et al., 2008;
Terracciano et al., 2008). Some researchers have assumed
neither an association between extraversion and CE-drug use
specifically (Middendorff et al., 2012), nor with substance use in
general (Turiano et al., 2012). However, several studies disprove
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this assumption. For example, it has been found that higher
extraversion correlates with increased alcohol consumption
(Turiano et al., 2012), more tolerant attitudes toward substance
use (Francis, 1996), and more frequent use of substances
including cigarettes, alcohol, and recreational drugs (Atherton
et al., 2014). Yet, the association between extraversion and
substance use may depend on the specific substance in question.
Studies found that extraversion was higher in smokers as well
as marijuana and cocaine/heroin users (Terracciano et al., 2008)
but lower for opioid dependents (Kornør and Nordvik, 2007). A
broad CE-measure, however, was uncorrelated with extraversion.
Agreeableness can be defined as a person’s pro-social and
communal orientation and includes a person’s tendency to be
altruistic, trustworthy, cooperative, considerate, empathic, polite,
andmodest (Caspi et al., 2005; John et al., 2008; Terracciano et al.,
2008). While it has been assumed that agreeableness associates
negatively with substance use (Booth-Kewley and Vickers, 1994;
Turiano et al., 2012), for CE-drug use specifically it has been
predicted that there would be no effect (Middendorff et al.,
2012). This latter assumption has been supported by one study
(Middendorff et al., 2012). For other substances, agreeableness
seems to have a protecting effect, since more agreeable persons
report lower marijuana use (Terracciano et al., 2008), alcohol
consumption (Malouff et al., 2007; Turiano et al., 2012), non-
medical use of prescription drugs (Benotsch et al., 2013),
polydrug abuse (Lackner et al., 2013), and alcohol dependency
(Kornør and Nordvik, 2007).
Neuroticism includes feelings such as anxiety, nervousness,
sadness, and depression and thus reflects a tendency to
experience negative emotions (Caspi et al., 2005; John et al., 2008;
Terracciano et al., 2008). Neuroticism is seen as a risk factor for
CE-drug use (Middendorff et al., 2012) and more generally for
the non-medical use of prescription drugs as well (Benotsch et al.,
2013), but also for the use of other substances (Turiano et al.,
2012). According to the self-medication hypothesis (Khantzian,
1997; West, 2005), individuals use drugs and may become
dependent on them because they are vulnerable to stress,
emotionally unstable, and thus may use CE to cope with
emotional distress (Kornør and Nordvik, 2007; Benotsch et al.,
2013). Contrary to these assumptions, neurotic individuals might
also be more anxious about the potential side effects of CE-drug
use, which might inhibit their use. However, several studies have
corroborated that more neurotic individuals report higher use of
a variety of substances, e.g., a broad CE-measure (Middendorff
et al., 2012), alcohol consumption (Malouff et al., 2007; Turiano
et al., 2012), cigarette smoking (Terracciano et al., 2008; Turiano
et al., 2012), illegal drug use (Turiano et al., 2012) including
cocaine and heroin (Benotsch et al., 2013), and prescription drug
use especially anxiolytics and sedatives (Turiano et al., 2012;
Benotsch et al., 2013); they are also more likely to report polydrug
addiction (Lackner et al., 2013) and drug use disorder (Sher et al.,
2000).
Due to scarce data on CE-drug use and the FFM and given
the often inconsistent correlations between Big Five dimensions
andmany kinds of substance use andmisuse from heterogeneous
studies, there is a clear need for more research in this field (e.g.,
Booth-Kewley and Vickers, 1994; Francis, 1996; Malouff et al.,
2007; Terracciano et al., 2008; Turiano et al., 2012; Benotsch et al.,
2013; Lackner et al., 2013; Atherton et al., 2014).
By using data from a representative, large-scale random
sample of German employees, this study aims at expanding our
understanding of the prevalence of prior non-medical use of
prescription drugs (a retrospective measure) and the willingness
to use such drugs in the future (a prospective measure) with the
subjective purpose of augmenting one’s cognitive performance
(by improving functions such as concentration, memory, or
vigilance) as well as the association between the prevalence and
willingness and the FFM traits. On a more general level, the
study also adds to our understanding of the effect of personality
traits on substance use: although mainly illicit drugs as well as
substances such as alcohol and nicotine have been investigated in
this regard, the non-medical use of prescription drugs has less
frequently been the subject of research (Benotsch et al., 2013;
N’Goran et al., 2014). Moreover, several studies on substance use
and personality traits have investigated only one or a subset of
traits of the FFM, while the present study investigates all five
domains (Booth-Kewley and Vickers, 1994; Turiano et al., 2012;
N’Goran et al., 2014).
METHODS
Research Design and Data
Data
The data for this study are based on the first wave of the B3
Linked Employer-Employee Panel Survey (LEEP-B3) (Diewald
et al., 2014). For the purpose at hand, we use the employee-
survey of the LEEP-B3 data, which were collected as computer-
assisted telephone interviews (CATI) in 2012–13 in Germany.
Prior to the interviews selected participants were informed by
a cover letter about the subject of the study, the voluntariness
of their participation, their anonymity, and the confidentiality
of all their answers. These issues were explained again during
the first telephone contact. The underlying population comprises
all employees in Germany who are subject to social security
contributions, which applies to the majority of German
employees—excluding only self-employed, marginally employed,
apprentices, and civil servants. The net sample comprised 21,678
eligible respondents. The response rate was 29.77%, which leads
to a total sample of 6454 (Diewald et al., 2014). Multivariate
selectivity analyses comparing the sample to the underlying
population using German registry data indicate that the LEEP-
B3 data represent the underlying population rather well (Diewald
et al., 2014). There is some limited selectivity, namely people
who are German nationals and work in the “information and
communication” sector participated in greater numbers, whereas
people with lower levels of education and those working in very
large organizations were less likely to participate.
Ethics Statement
In Germany, ethics approval for social science research is not
required if research objectives do not investigate issues regulated
by law (e.g., the German Medicine Act [Arzneimittelgesetz,
AMG], the Medical Devices Act [Medizinproduktegesetz, MGP],
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the Stem Cell Research Act [Stammzellenforschungsgesetz,
StFG], or theMedical Association’s Professional Code of Conduct
[Berufsordnung der Ärzte]). Since our study had no such
objectives, approval was not required. Furthermore, paragraph
28 of the Data Protection Act of North Rhine Westphalia
(Datenschutzgesetz Nordrhein-Westfalen, DSG NRW) explains
that personal data have to be processed anonymously and that
participants’ consent is required only when the data are not
used anonymously. Since data were collected in cooperation
with the federal Institute for Employment Research (Institut
für Arbeitsmarkt und Berufsforschung, IAB; Diewald et al.,
2014), the study and all procedures were approved by the data
security officer of the federal IAB and the Federal Ministry of
Labor and Social Affairs (Bundesministerium für Arbeit und
Soziales, BAMS). Prior to the interviews the selected participants
were informed by a cover letter about the subject of the
study. This letter explicitly informed the potential participants
of the voluntariness of their participation, their anonymity,
and the confidentiality of all their answers. During the first
telephone contact, potential participants were again explicitly
informed that their participation was voluntary, that all answers
would be treated confidentially, and that the data would be
anonymized. Thus, the act of participating in the study after
receiving all relevant confidentiality information was taken to
imply understanding and agreement.
Measures
Prior CE-Drug Use
We measured prior CE-drug use by asking: “Some people
support their cognitive abilities with the help of prescription
drugs, though there is no medical need (e.g., for increasing
concentration, memory, or vigilance). Have you ever done that?”
We provided the following response categories: “no, never” (0);
“yes, within the last 30 days” (1); “yes, between the last 30
days and 6 months” (2); “yes, between the last 6 months and
1 year” (3); “yes, more than 1 year ago” (4) (cf. Sattler and
Wiegel, 2013; Wiegel et al., 2015). Due to the low prevalence
(see Table 1), a dichotomous variable was computed for our
multivariate analysis, indicating no use (0) and prior use (1) (cf.
Wiegel et al., 2015).
Willingness to Use CE Drugs
Given that CE-drug use can be described as a relatively new
and potentially increasing phenomenon (e.g., Farah et al.,
2004; Castaldi et al., 2012), we also assessed the respondents’
willingness to use CE drugs, since this can be seen as one
method for determining whether the postulated trend exists
(Wiegel et al., 2015). Willingness measures are often used in
research on the use of (licit and illicit) substances such as
tobacco, alcohol, amphetamines, and marijuana, since they are
used as proximal antecedents of future behavior (Gibbons et al.,
1998a,b; Gerrard et al., 2006). However, an imperfect correlation
between this measure and behavior may exist, since behavioral
restrictions can change over time (cf. Grasmick and Bursik,
1990). But such measures are assumed to be less sensitive than
behavioral measures and thus should result in fewer item-non
responses or biased responses (e.g., Gibbons et al., 1998b). The
CE-willingness measure was similar to the prior CE-drug use
measure. Respondents were asked whether they could imagine
using (or reusing) such prescription drugs for CE in the future
(cf. Ponnet et al., 2015; Wiegel et al., 2015). Dichotomous
response categories were “No, I would not do that under any
circumstances” (0) and “Yes, I would do that under certain
circumstances” (1) (cf. ZUMA, 1990).
Personality Traits
We used a short version of the Big Five Personality Traits
Inventory (BFI-S) (Gerlitz and Schupp, 2005; Dehne and Schupp,
2007; Hahn et al., 2012) to assess the components of the FFM
of personality (e.g., Costa and McCrae, 1995). Each of the five
factors (openness to experience, conscientiousness, extraversion,
agreeableness, and neuroticism) were measured by three items
on five-point scales ranging from “I agree entirely” (1) to “I
do not agree at all” (5). The items have been reverse-coded
so that higher values indicate stronger agreement with the
underlying factor (see Table S1). With regard to reliability,
the BFI-S is a reasonable instrument for measuring the FFM
in large, multi-purpose surveys (Lang et al., 2011). Similar to
prior research (Dehne and Schupp, 2007), reliability analysis
of the scales showed moderate internal consistencies: openness
to experiences (artistic experiences, ideas, active imagination,
α= 0.53), extraversion (talkative, sociable, reserved, α = 0.66),
conscientiousness (efficient, thorough job, lazy, α = 0.55),
agreeableness (forgiving, kind, rude, α = 0.45), and neuroticism
(worried, nervous, relaxed, α = 0.54). However, since each item
is supposed to measure a distinct facet within each dimension,
the relatively low alpha values can be seen as an indication of
the distinctness of the underlying facets (Rammstedt, 2010). We
used explanatory factor analysis with varimax rotation to extract
the five factors from the BFI-S (see Table S1). All items loaded
substantially on the respective factor (openness with a mean
factor loading of 0.68; extraversion with a mean factor loading
of 0.76; conscientiousness with a mean factor loading of 0.69;
agreeableness with amean factor loading of 0.66; and neuroticism
with a mean factor loading of 0.71) and showed low secondary
loadings on other factors (mean secondary loading= 0.07).
Demographic Variables
Women were coded “0” and men “1” (see Table 1 for this and
other descriptive statistics). We also assessed gender (female = 0
and male = 1), age, education in years (each educational degree
is assigned the average duration it takes to obtain), and personal
gross monthly earnings in Euro.
Missing Values
The proportion of missing values is generally low (see Table 1).
The highest proportion of missings can be found with earnings
(4.93%, n = 318). Missing values were imputed using
multivariate imputation by chained equations (MICE) (Azur
et al., 2011; White et al., 2011) with 20 data sets. The following
multivariate analyses are based on the imputed data sets, but all
analyses have also been carried out using the unimputed data set
(see Tables S2, S3).
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TABLE 1 | Descriptive statistics with non-imputed data.
Mean Standard deviation Min Max Observations Observations with
missing values (in %)
COGNITIVE ENHANCEMENT
Prior CE-drug usea 0.03 – 0.00 1.00 6444 10 (0.15)
Willingness to use CE drugs 0.10 – 0.00 1.00 6332 122 (1.89)
BIG FIVE PERSONALITY TRAITS INVENTORY
Openness to experiences 0.00 1.00 −3.76 2.92 6407 47 (0.73)
Conscientiousness 0.00 1.00 −5.89 2.82 6407 47 (0.73)
Extraversion 0.00 1.00 −3.46 2.49 6407 47 (0.73)
Agreeableness 0.00 1.00 −4.84 2.60 6407 47 (0.73)
Neuroticism 0.00 1.00 −3.02 3.46 6407 47 (0.73)
SOCIO-DEMOGRAPHIC CONTROLS
Male 0.53 – 0.00 1.00 6454 0 (0.00)
Age in years 40.63 8.64 19.00 52.00 6454 0 (0.00)
Education in years 14.04 2.83 7.00 18.00 6408 46 (0.71)
Gross monthly earnings in Euro 3766.70 3650.65 13.27 125,000.00 6136 318 (4.93)
Source: LEEP-B3, own computations.
aThis category includes 50 (0.78%) respondents indicating CE-drug use within the last 30 days, 24 (0.37%) respondents indicating such usage between the last 30 days and 6 months,
27 (0.42%) respondents indicating such usage between the last 6 months and 1 year and 90 respondents (1.40%) indicating that such usage was more than 1 year ago.
Statistical Analysis
We used logistic regression models to test how the dependent
variables covary with the independent variables. We report odds
ratios (OR). ORs greater than 1 indicate positives effects of
the independent variables on the respective dependent variable,
while ORs lower than 1 indicate a negative effect, and ORs equal
to 1 indicate no effect. The reported p-values are based on robust
standard errors.
RESULTS
Prior CE-Drug Use
Our descriptive results (based on non-imputed data) show that
approximately 97.04% (n = 6253) of the respondents report
that they have never used prescription medication non-medically
to support their cognitive abilities (see Table 1), while 2.96%
(n = 191) reported such CE-drug use during their lifetime (see
Table 1). In particular, 0.78% (n = 50) reported having used
such drugs within the last 30 days, 0.37% (n = 24) between
the last 30 days and 6 months, 0.42% (n = 27) between the
last 6 months and 1 year, and 1.40% (n = 90) reported having
used such drugs over a year ago. Our multivariate analysis (based
on imputed data) focuses on the lifetime prevalence of CE-
drug use only (see Methods section). Results show an OR of
0.774 (p < 0.001) in Model 1 in Table 2, which indicates a
significant negative association between conscientiousness and
prior CE-drug use. Thus, more conscientious respondents had
a lower probability of prior CE-drug use. Moreover, we found
a positive association between neuroticism and CE-drug use
(p < 0.001). No significant associations were found for openness
to experiences (p = 0.101), extraversion (p = 0.416), or
agreeableness (p = 0.376). Prior use of CE drugs did not
significantly vary with the socio-demographic controls gender
(p = 0.865), age (p = 0.811), and earnings (p = 0.404)2.
Education, however, was found to have a negative association
with prior CE-drug use (p = 0.049).
Willingness to Use CE Drugs
10.45% (n = 662, based on non-imputed data) of the respondents
reported being willing to consume CE drugs in the future, while
the remaining 89.55% (n = 5.670) indicated that they would
never use such drugs (see Table 1). Multivariate analysis (based
on imputed data) shows that the willingness to use CE drugs
decreased if respondents showed stronger tendencies toward
conscientiousness (p < 0.001) and it increased if respondents
reported higher levels of neuroticism (p < 0.001) (see Model
2 in Table 2). Again, the effects for the domains openness
to experience (p = 0.687), extraversion (p = 0.128), and
agreeableness (p = 0.080) reached no conventional levels of
significance. Males were less willing to use CE drugs in the future
compared to females (p = 0.012). Age (p = 0.320), education
(p = 0.414), and earnings (p = 0.848) had no significant effects
on the willingness to use CE drugs3. Respondents reporting the
use of CE drugs in the past were much more willing to consume
such drugs in the future compared to those who had never used
such drugs (p < 0.001; Table 2, Model 3). Finally, we tested
whether the effects of the five personality domains and the socio-
demographic variables were conditional on prior use by adding
interaction terms of these variables with prior use (see Table
S3). Results show that no differential effects exist, i.e., the effects
of the five personality domains and the socio-demographics on
2In line with a developmental framework (e.g.,McLarnon et al., 2012), individuals
in different stages of life might have different demands or propensities to use CE
drugs (e.g., due to different peer exposure, risk preferences, or stressful periods).
We therefore additionally tested quadratic and cubic functions of the age effect.
Because no such effects were found, we do not show the results.
3Again, quadratic and cubic functions of the age effect were not significant.
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TABLE 2 | Logistic regression models to assess associations of the BFI-S and socio-demographic controls with prior CE-drug use (Model 1) and the
willingness to use CE drugs (Model 2 and 3) with imputed data (Number of imputations = 20, Number of observations = 6454).
Model 1 Model 2 Model 3
Prior CE-drug use Willingness to use CE drugs Willingness to use CE drugs
OR 95% CI OR 95% CI OR 95% CI
Openness to experience 1.129 [0.977, 1.305] 1.018 [0.935, 1.107] 0.999 [0.914, 1.092]
Conscientiousness 0.774*** [0.674, 0.888] 0.810*** [0.748, 0.876] 0.831*** [0.766, 0.903]
Extraversion 1.061 [0.919, 1.225] 1.067 [0.981, 1.159] 1.062 [0.975, 1.158]
Agreeableness 0.941 [0.822, 1.077] 0.931 [0.859, 1.009] 0.934 [0.858, 1.017]
Neuroticism 1.352*** [1.154, 1.584] 1.303*** [1.197, 1.418] 1.264*** [1.158, 1.379]
Male 0.865 [0.628, 1.192] 0.798* [0.669, 0.951] 0.802* [0.667, 0.964]
Age in years 0.998 [0.981, 1.015] 1.005 [0.995, 1.015] 1.006 [0.996, 1.016]
Education in years 0.944* [0.891, 1.000] 0.988 [0.958, 1.018] 0.997 [0.966, 1.029]
Gross monthly earnings in Euro 1.000 [1.000, 1.000] 1.000 [1.000, 1.000] 1.000 [1.000, 1.000]
Prior CE-drug use 17.320*** [12.608, 23.792]
Constant 0.080*** [0.025, 0.256] 0.120*** [0.066, 0.220] 0.083*** [0.045, 0.156]
Log pseudolikelihood −840.449 −2114.087 −1955.289
Pseudo R² 0.026 0.021 0.094
Source: LEEP-B3, own computations.
OR = Odds Ratios. CI = 95% confidence intervals in parentheses (based on robust standard errors). Log pseudolikelihood and Pseudo R2 are averaged across imputed datasets.
*p < 0.05, **p < 0.01, ***p < 0.001.
the willingness to use CE drugs do not differ between users and
non-users.
To facilitate the interpretation, the main results concerning
the association between prior CE-drug use and the two
personality traits of conscientiousness and neuroticism as well as
the association betweenwillingness to use CE drugs and these two
traits are displayed in Figure 1. It shows predicted probabilities
for both CE-measures using average marginal effects based on
the multivariate models in Table 2. The predicted probabilities
show that the effects associated with conscientiousness and
neuroticism are rather large. The predicted difference between
respondents with a low [defined by the mean (M) minus one
standard deviation (SD)] and a high level of conscientiousness
(M + 1 SD) is 39 percentage points (3.71 vs. 2.26%) in prior
use and 31 percentage points regarding willingness to use (12.38
vs. 8.51%) (Figures 1A,C). As regards neuroticism, the predicted
difference between respondents with a high level (M + 1 SD)
and respondents with a low level (M – 1 SD) of this personality
trait is 44 percentage points in prior use (3.76 vs. 2.10%) and 38
percentage points in willingness to use CE drugs (12.78 vs. 7.98%)
(Figures 1B,D).
DISCUSSION
Summary and Interpretation of the Results
Prevalence of CE-Drug Use and the Willingness to
Take CE Drugs
While there is a fierce debate about whether CE-drug use
is already a widespread phenomenon or whether it will be
widespread in the future (Sahakian and Morein-Zamir, 2007;
Greely et al., 2008; Ragan et al., 2013; Sattler et al., 2013a),
limited research has been based on prevalence estimates derived
from large-scale random samples beyond student populations
(Hoebel et al., 2011; Mache et al., 2012; Sattler et al., 2013a;
Fitz et al., 2014; Sattler, in press). We add to this research
with data from more than six thousand employees in Germany
randomly selected for this study (Diewald et al., 2014). We found
a lifetime prevalence of nearly 3% for use of prescription drugs
for supporting cognitive performance. This figure falls in the
range of prevalence estimates of comparable prior studies (DAK
Gesundheitsreport, 2009; Hoebel et al., 2011; Marschall et al.,
2015) and shows that CE-drug use is already a fact, even if
not a general practice, which opposes the current media hype
about CE. Still, it has been estimated that more than half a
million individuals in Germany have experience with CE-drug
use (Kowalski, 2013); it can be presumed that a large number
of these continue using (Sattler and Wiegel, 2013; Sattler et al.,
2014; Wiegel et al., 2015), risking potential detrimental health
effects often with no real effects or even detrimental effects.
But the willingness to use such drugs in the future was more
than three times greater than lifetime prevalence. More than
every 10th respondent indicated such a willingness. A similar
difference between prior and potential future use has been found
in a study of university teachers (Wiegel et al., 2015). Of course
expressed willingness does not necessarily translates into actual
behavior, for example due to changes in behavioral restrictions
(cf. Grasmick and Bursik, 1990). However, discrepancies between
willingness and use of CE drugs may also be explained by
other factors. For example, potential users may not yet have
experienced a pressing need to take such drugs, but would do
so if the need were to occur, or they might not have had the
opportunity (e.g., due to lack of access) to convert their interest
into use (Singh et al., 2014; Wiegel et al., 2015). But drugs may
become more available via the Internet and on the black market
(Sahakian and Morein-Zamir, 2007). Potential users may also
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FIGURE 1 | Predicted probabilities of prior use and willingness (both y-axis) estimated using average marginal effects based on multivariate logistic
regression models—error bars represent the 95% confidence interval. (A) shows that the predicted probability of prior CE-drug use is higher in case of lower
conscientiousness [defined by the mean value (M) − 1 standard deviation (SD)] compared to theM and to higher conscientiousness (M + 1 SD), while the probability
(B) is lower for lower levels of neuroticism (M – 1 SD) compared to theM and to higher neuroticism (M + 1 SD) (based on Model 1, Table 2). (C,D) show similar effects
for the willingness to use CE drugs (based on Model 2, Table 2).
want to wait until more effective and safer medication is available
(DAK Gesundheitsreport, 2009; Franke et al., 2012; Wiegel et al.,
2015).
Associations between Big Five Personality Traits and
Prior CE-Drug Use and the Willingness to Engage in
CE-Drug Use
Only relatively few studies (e.g.,Franke et al., 2012, 2013; Sattler
and Wiegel, 2013; Wolff and Brand, 2013; Sattler et al., 2014;
Wiegel et al., 2015; Maier et al., 2015) have responded to one of
the first appeals for investigating how personality relates to CE-
drug use (Quednow, 2010); in these the Big Five traits—which
represent an important set of traits—have generally been ignored,
with the exception of one study among students (Middendorff
et al., 2012). By investigating the association between Big Five
traits and prior CE-drug use as well as the willingness to use
CE drugs in the future, we hope to add to our understanding
of how a set of five major personality traits relates to such
behavior. This also contributes to the often inconsistent findings
between various kinds of substance use and misuse (including
tobacco, alcohol, prescription stimulants, marihuana, etc.) and
the FFM (e.g., Booth-Kewley and Vickers, 1994; Francis, 1996;
Malouff et al., 2007; Terracciano et al., 2008; Turiano et al.,
2012; Benotsch et al., 2013; Lackner et al., 2013; Atherton et al.,
2014).
Similarly to a study of students using a broad retrospective
measure of CE that combines certain prescription, non-
prescription, and illegal drugs (Middendorff et al., 2012),
we found that openness to experience was unrelated to
both prior CE-drug use and the willingness measure. This,
however, contradicts the assumption that the tendency to engage
in new experiences and a greater eagerness to experiment
produce a risk factor of higher involvement in substance
use (Middendorff et al., 2012; Turiano et al., 2012; Benotsch
et al., 2013). It also contradicts several findings regarding
the use of multiple substances (e.g., illegal drug use, cigarette
smoking, the non-medical use of prescription drugs), which
found associations consistent with this assumption (e.g., Booth-
Kewley and Vickers, 1994; Trull and Sher, 1994; Kornør and
Nordvik, 2007; Terracciano et al., 2008; Turiano et al., 2012;
Benotsch et al., 2013).
Respondents with higher levels of conscientiousness were
less likely to report prior CE-drug use as well as a willingness
to use CE drugs in the future. This is consistent with the
supposition that conscientiousness serves as a protective factor
against substance use (Middendorff et al., 2012; Turiano et al.,
2012; Benotsch et al., 2013) and corroborates prior findings on
a broad CE-drug measure (Middendorff et al., 2012) as well as
many other substances such as alcohol consumption, cigarette
smoking, prescription drug use, and illegal drug use (e.g., Trull
and Sher, 1994; Kornør and Nordvik, 2007; Malouff et al., 2007;
Terracciano et al., 2008; Turiano et al., 2012; Benotsch et al., 2013;
Lackner et al., 2013; Atherton et al., 2014). This protective effect
could be due to better self-regulation and persistence, which help
to control impulses and delay the immediate gratifications of
potentially health-damaging behaviors, while aiming for positive,
long-term outcomes (such as long-term health) (Middendorff
et al., 2012; Benotsch et al., 2013; Turiano et al., 2012). But also a
greater ability to engage in systematic and organized behavior and
consequently achieving better performance outcomes reduces the
need to use CE drugs to compensate for the lack of such an ability
(Middendorff et al., 2012). Furthermore, the increased tendency
of conscientious individuals to follow norms might also decrease
their likelihood to engage in behavior that many consider as
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morally objectionable (Sattler et al., 2013b; Dubljevic´ et al., 2014;
Schelle et al., 2014; Wiegel et al., 2015; Sattler, in press).
Our results also show no significant covariation between
extraversion and our two CE-measures. This finding
corroborates researchers’ assumption that no such association
should exist (Middendorff et al., 2012; Turiano et al., 2012)
as well as the results of one study that found no association
between CE-drug use and extraversion (Middendorff et al.,
2012); at the same time some studies found that higher levels of
extraversion can be associated with increased consumption of
several substances (e.g., Kornør and Nordvik, 2007; Terracciano
et al., 2008; Turiano et al., 2012; Atherton et al., 2014).
Agreeableness was neither significantly associated with our
retrospective nor with the prospective CE-measure and thereby
supports prior research on agreeableness and CE as well as the
assumption that no such effect exists (Middendorff et al., 2012).
For the use of other substances a negative association has been
predicted (Booth-Kewley and Vickers, 1994; Turiano et al., 2012)
and found (e.g., Kornør and Nordvik, 2007; Malouff et al., 2007;
Terracciano et al., 2008; Turiano et al., 2012; Benotsch et al., 2013;
Lackner et al., 2013), showing that agreeableness seems to have a
protective effect.
It has also been shown that increased neuroticism leads
to higher probabilities of prior CE-drug use and willingness
to use CE drugs. Our results thus support the assumption
that neuroticism is a risk factor for several kinds of substance
use (Middendorff et al., 2012; Turiano et al., 2012; Benotsch
et al., 2013). They also corroborate prior findings on a broad
CE-measure (Middendorff et al., 2012) and other substances
including prescription drugs, alcohol, nicotine, and illegal drugs
(Sher et al., 2000; Malouff et al., 2007; Terracciano et al., 2008;
Turiano et al., 2012; Benotsch et al., 2013; Lackner et al., 2013).
One reason for these findings could be that neurotic individuals
are less emotionally stable and more vulnerable to stress and
therefore use these substances to cope with emotional distress
(Kornør and Nordvik, 2007; Benotsch et al., 2013).
Associations Between Demographic Controls and
Prior CE-Drug Use and Willingness to Engage in
CE-Drug Use
With regard to the demographic controls, we found almost
no significant differences regarding prior and potential future
CE-drug use. While prior studies have shown mixed gender
effects—generally finding no effect or a higher prevalence for
males, but also that the purpose of use or the types of drugs
used differ between sexes (e.g., McCabe et al., 2005; Rabiner
et al., 2009, 2010; Weyandt et al., 2009; Ford and Ong, 2014;
Singh et al., 2014; Ponnet et al., 2015; Wiegel et al., 2015)—
our study found that women showed a higher willingness to
use CE drugs, which is consistent with another German large-
scale study (Hoebel et al., 2011). It has been assumed that such
effects could indicate structural discrimination against women,
namely that women need to work harder than men to rise in the
hierarchy and at the same time often have twice or three times
the amount of chores (work, children, and household) (Wiegel
et al., 2015). This might increase the incentive for women to use
such drugs as leverage in the job and to deal with their larger
workload. Prior findings about the age-effect were indecisive
(e.g., Maher, 2008; Terracciano et al., 2008; Benotsch et al., 2013;
Ragan et al., 2013; Sattler and Wiegel, 2013; Sattler et al., 2013a;
Ford and Ong, 2014; Singh et al., 2014; Wiegel et al., 2015),
however, we found no age effect for both outcome variables.
More years of education, however, were associated with a lower
reporting of prior CE-drug use, which contradicts, for example,
the study of Hoebel et al. (2011), which found no significant
differences. One explanation could be that increased education
is associated with greater knowledge about the limited efficiency
of CE drugs. Additionally, for those with lower education, CE
could be one means of compensating for lowered chances in
the labor market or of dealing with potentially burdensome
demands from their jobs. These assumptions have to be verified
by future research. Respondents with potentially more monthly
financial resources reported no elevated prior CE-drug use or
willingness to do so in the future. In keeping with prior findings
(Sattler and Wiegel, 2013; Sattler et al., 2014; Wiegel et al.,
2015) and reasoning consistent with the Theory of Planned
Behavior (Beck and Ajzen, 1991; Ouellette and Wood, 1998),
we found a strong positive effect of prior CE-drug use on the
willingness to consume such drugs in the future, indicating that
many users have not only experimented once with these drugs
but intend to continue using them (cf. Müller and Schumann,
2011). Users may have already made up their minds about their
preferences or may be influenced by other factors such as a
lack of self-control, sticking with their decisions out of habit
and without further deliberation; they may have had positive
experiences; or, in order to reduce potential cognitive dissonance,
they may justify prior and continued drug consumption by
ignoring negative information about CE-drug use or perceiving
supporting information on a selective basis (Beck and Ajzen,
1991; Ouellette andWood, 1998; Caviola et al., 2014;Wiegel et al.,
2015).
Limitations and Strengths of the Study and
Directions for Future Research
The awareness of potential limitations is important when
interpreting our results. We will describe these together with the
strengths of our study as well as suggest directions for future
research:
1. Our response rate of 29.77% can be compared to similar
studies (Bender et al., 2009; Schmich, 2015). But a considerable
amount of invitees did not participate in our survey,
which can reduce the external validity of the results if this
non-response is selective. However, a comparison between
the target population (information derived from German
registry data) and our sample shows a high correspondence
between socio-demographic characteristics, indicating limited
problems of selectivity (see Methods section) (Diewald et al.,
2014). Since we used a large representative population-
based sample, our results might be more generalizable
than the numerous small scale and non-representative
samples in the field of CE-research and of research on the
association between BFI and the non-medical use prescription
drugs.
2. Our sample covers only the employed German population
subject to social insurance contributions, hence it does not
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provide a full picture of the general population in Germany.
However, our target population can be considered a large and
important group in society. More research has been requested
for our under-investigated target population (Greely et al.,
2008; Ragan et al., 2013; Fitz et al., 2014; Schelle et al.,
2014; Sattler, in press). This request is due to the repeated
critique thatmost prior studies on factors influencing CE-drug
use solely focused on students or other specific populations
(Cutler, 2014; Ford and Ong, 2014; Wolff et al., 2014; Maier
et al., 2015; Wiegel et al., 2015) and thus faced a limited
generalizability.
3. We only investigated individuals from one country. CE-drug
use as well as the association between CE and BFI might differ
across countries, for example, due to varying regulations,
social acceptance, advertisement, and the availability of CE
drugs as well as (legal and illegal) alternative drugs that serve
as substitutes (cf. Terracciano et al., 2008; Bell et al., 2013;
N’Goran et al., 2014; Wiegel et al., 2015; Sattler, in press).
Studies in other countries using a methodology similar to ours
could provide insights about the cross-cultural generalizability
of our results.
4. Several studies investigating the relationships between
personality traits and (non-medical) drug (mis-)use
investigate only a subset of Big Five traits (Terracciano
et al., 2008). We assessed all five domains and thus can offer
a more complete picture of these relationships. Since we
could only employ a short scale of the Big Five Personality
Traits Inventory (Gerlitz and Schupp, 2005; Dehne and
Schupp, 2007; Hahn et al., 2012), only overall effects of
the five higher level personality factors were explored (cf.
Turiano et al., 2012). The BFI-S showed only moderate
values concerning reliability, which has been documented
in previous research (Dehne and Schupp, 2007). However,
one would not expect high alpha values if each (single)
item is supposed to capture a specific facet within a trait
(Rammstedt, 2010). More importantly, however, the factor
loadings were high and unambiguous, indicating that the
BFI-S captures the underlying latent personality dimensions
rather well. Still, future studies should investigate the full
BFI or the NEO-PI-R (Berth and Goldschmidt, 2004;
Ostendorf and Angleitner, 2004; Soto and John, 2009) to
see if the results can be replicated with broader measures
of personality and which lower level personality-facets
of each trait are specifically relevant and predictive due
to their higher specificity. It has been argued, however,
that interpreting effects of domains is more basic and
“combines information from several scales in meaningful
ways and allows us to make more powerful inferences
about personality traits and correlates that are not directly
measured” (Costa and McCrae, 1995, p. 46). In addition
to these instruments that target the Big Five traits, other
personality trait inventories as well should be employed
in future studies, such as the Minnesota Multiphasic
Personality Inventory (MMPI) (e.g., Butcher, 2010), the
16PF Questionnaire (e.g., Cattell and Mead, 2008), or the
Myers-Briggs Type Indicator (MBTI) (e.g., Myers et al.,
1985).
5. Self-reporting CE-drug use can be seen as sensitive and thus
may provoke drop-out, non-response, and underreporting4
—especially if the anonymity of respondents is not guaranteed
(Benotsch et al., 2013; Sattler, in press). This undoubtedly
causes downward-biased prevalence estimates. In our
telephone study, it was not possible to employ other measures
such as testing hair, urine, or blood and contrast these
results with self-report measures. But individuals might be
reluctant to allow such tests (cf. N’Goran et al., 2014), which
can thus also lead to distorted prevalence estimates due to
selection bias. We did, however, inform the participants
verbally and in writing about the measures to ensure the
anonymity of their participation. Our results also show that
item-nonresponse was considerably low (0.15% for prior
CE-drug, and 1.89% for the willingness measure), which can
be one indication of relatively low perceived sensitivity of
the question resulting in a high confidentiality of answering
(Sattler et al., 2013a). We calculated all models with raw
data and after applying the multiple imputation procedure
to test whether dropout and item-nonresponse affected our
results. Our analysis show that the results are highly similar
(see Tables S2, S3), which testifies to the robustness of our
results.
6. Due to the low prevalence of CE-drug use, we only employed
a lifetime prevalence measure of CE-drug use. However,
future studies should distinguish periods of use (e.g., the 1-
month or 12-months prevalence) more precisely, investigate
frequency measures (e.g., to differentiate between regular
use and one-time use), assess the dosage (e.g., to assess the
severity of misuse), run drug-specific analyses, and investigate
single- and poly-substance use (Turiano et al., 2012; Sattler
and Wiegel, 2013; N’Goran et al., 2014; Sattler, in press)
to further increase our understanding of the association
between BFI and CE. As a second outcome variable, we
probed the respondents about their potential future use of CE-
drugs in general. Future studies could detail this by assessing
willingness for specific situations and in specific contexts (e.g.,
in high stress situations). Such measure can be developed
also in order to differentiate between behavioral willingness
and behavioral intentions, e.g., in order to test the Prototype-
Willingness Model (Gibbons et al., 1998a,b, 2009; Gerrard
et al., 2006).
7. Another caveat of our research is associated with the use
of cross-sectional data, implying that conclusions about the
causal effect of personality are not warranted. Some scholars
argue that drug use may cause changes in personality traits
(Caspi et al., 2005; Normann and Berger, 2008; Kipke et al.,
2010). Following this argument, the associations between the
personality traits investigated and CE-drug use could be at
least partially explained by drug-induced personality changes.
To our knowledge no such research exists (yet) for CE-drug
use, but it does for other substances (Bates and Pandina, 1991;
Littlefield et al., 2010; Hicks et al., 2012; Hulka et al., 2015)
4Over-reporting might occur in rare cases, but it is assumed to be less likely in
our context since most people in prior studies voiced moral objections to using
CE-drugs Sattler et al., 2013a,b; Schelle et al., 2014; Wiegel et al., 2015.
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and it could be assumed that such effects are possible for
CE-drug use as well. On the other hand, it has been argued
that personality traits are relatively stable entities (Costa and
McCrae, 1988; Soldz and Vaillant, 1999; Caspi et al., 2005;
Terracciano et al., 2006; Turiano et al., 2012) and it has
been assumed that they might not change rapidly through
CE-drug use (Metzinger, 2012; Wulf et al., 2012), whereas
some research has shown trait changes for other substances
after as little as a few weeks or months (Tang et al., 2009).
One study has shown that personality still had predictive
power if there was a long time-lag between the assessment of
personality and substance use (Turiano et al., 2012). But this
study also found that personality changes affected substance
use. These findings call for more longitudinal research to
assess the covariation of personality and CE-drug use or
substance use in general over time (Sher et al., 2000; Turiano
et al., 2012; N’Goran et al., 2014). However, our results
show that the associations found between the willingness
measure and the personality traits was similar for non-
users and users. Thus, those who did not experience any
potential personality changes from CE-drug use did not show
a different willingness to use such drugs, which corroborates
the effects on prior CE-drug use we found for personality
traits. But still, our assessment of prior use did not cover
the frequency, dosage, or duration of use, which can be
seen as affecting substance-induced personality change. In
addition, unmeasured confounder variables (such as genetic
dispositions or social capital) could influence both personality
and substance use, or personality could be influenced by these
kinds of third variables, mediating their effect on substance
use (Eysenck, 1999; Malouff et al., 2007; Schunck, 2014).
Taken together and according to the reasoning of Malouff
et al. (2007) on alcohol consumption, it is possible that (a)
personality leads to CE-drug use, (b) CE-drug use leads to
certain personality traits, (c) a third variable influences both,
(d) personality mediates the effect of a third variable, or e) a
combination of these effects is operating. Studies investigating
these possibilities should also investigate variables that might
influence the relationship between personality traits and CE-
drug use, such as stress, social pressure, etc. (Francis, 1996;
Benotsch et al., 2013). Data allowing such investigations do
not currently exist.
This exploratory study investigated how prior and future
CE-drug use and the Big Five traits are associated. To better
understand its findings and those of earlier studies on the Big Five
traits and various substances used for CE and other purposes,
future research should put more emphasis on developing a
coherent theoretical model. To test this model, more highly
elaborated and fine-grained measures should be employed in
order to challenge the robustness of our findings and obtain a
more thorough comprehension of the relationship.
Conclusion
This large-scale study is based on a random sample of employees
in Germany and shows that the use of prescription drugs to
augment cognitive performance among healthy individuals is an
empirical reality. However, this behavior is less widespread than
had been anticipated by many scholars and media reports. But
the significantly greater willingness to use CE drugs compared
to the lifetime prevalence may be indicative of a possible
increase in CE-drug use in the future. Still, the extent to which
willingness to use CE drugs translates into actual behavior must
be addressed in longitudinal studies. It remains to be discussed
which threshold of willingness and prevalence justifies further
prevention and regulation means. At the very least, a non-
negligible number of individuals already risks side-effects, long-
term health consequences, and the involvement of the criminal
justice system by using often non-efficient pharmaceutical agents.
These individuals may also contribute to pressuring others to use
such drugs, to increasing healthcare costs, and to other issues
discussed in the ethics debate (e.g., CE-drug use in relation
to the authenticity of users, fairness, or social inequality). This
study increases our understanding of potential psychological
factors that hamper or foster the use of CE drugs. We found
that high levels of conscientiousness were associated with
decreased retrospective/prospective consumption, while high
levels of neuroticism increased it. Such insights about personality
profiles could be used to inform the development of treatment
approaches tailored to these profiles in order to minimize
health problems (Booth-Kewley and Vickers, 1994; Terracciano
et al., 2008; Conrod et al., 2011). Another approach would
be to develop interventions to promote beneficial personality
traits (e.g., increasing conscientiousness) and thereby support
a positive change toward health-related behaviors in general
(Magidson et al., 2014; Hudson and Fraley, 2015). However, less
risky options for enhancing one’s cognitive performance (such as
sufficient sleep, seeking support, meditation, physical exercise)
should be promoted for those who want or must enhance their
performance (e.g., Bostrom and Sandberg, 2009; Dresler et al.,
2013; Maier and Schaub, 2015; Wiegel et al., 2015).
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